Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
Stocks · News reference
GSK Commences Tender Offer To Acquire Nuvalent At $124/Share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
8-K filing — Nuvalent, Inc. (NUVL)
Filed: 2026-07-15 AccNo: 0001193125-26-304126 Size: 257 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Halper Sadeh LLC is Investigating Whether LCII, NUVL, DAN, TMHC are Obtaining Fair Deals for their Shareholders
Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions to determine if shareholders are receiving fair deals. The investigations cover LCI Industries' sale to Patrick Industries, Nuvalent's acquisition by GSK, Dana Incorporated's merger with Eaton Corporation, and Taylor Morrison's sale to Berkshire Hathaway. The firm is examining potential securities law violations and breaches of fiduciary duties, particularly regarding insider benefits and terms that may limit competing offers.